Advertisement

Picture [iito] Made Without Love 650x80px
Organisation › Details

Biond Biologics Ltd.

Biond Biologics is a drug discovery and development company focused on developing innovative therapies for novel oncology targets by uncovering immunoregulatory pathways and by enabling the intracellular delivery of biologics. Biond aims to translate high quality science and out-of-the-box, disruptive thinking into transformational drugs for diseases with high unmet needs. The company's vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies. Biond's pipeline is based on internal research of newly discovered immune-checkpoints and immune-evasion mechanisms. Biond's leading development programs include BND-22, a multi-cell checkpoint inhibitor targeting ILT2, and BION-206, a novel agent developed for overcoming PD-1 blockade resistance by targeting soluble CD28; an immune evasion mechanism discovered by Biond scientists. In addition to its pipeline of immunotherapy agents, Biond is developing INspire – an innovative technological platform that enables the intracellular delivery of biologic agents into cells. INspire is based on a chemically modified carrier protein that can be conjugated to protein therapeutics, such as antibodies or enzymes, and is designed to deliver the conjugated therapeutic inside cells thus providing access to numerous, critical disease targets currently considered "undruggable". Biond was founded in 2016, by Tehila Ben-Moshe, Ph.D., Ori Shilo, and a team of accomplished scientists and drug developers from the Israel biopharmaceutical industry. The lead investors in the company are Israel Biotech fund ("IBF") and Harel Insurance. *

 

Period Start 2016-01-01 established
Products Industry cancer drug
  Industry 2 BND-22 (Biond Biologics / Sanofi)
     
Region Region Israel_oo
  Country Israel
  City n. a. Misgav
  Tel +972-4-8844337
    Address record changed: 2021-01-29
     
Basic data Employees n. a.
     
    * Document for �About Section�: Biond Biologics Ltd.. (1/12/21). "Press Release: Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor". Misgav.
     
   
Record changed: 2021-01-29

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Biond Biologics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top